European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Claus Garbe(University Children's Hospital Tübingen), Paul Lorigan(University of Manchester), Nicole W.J. Kelleners-Smeets(Maastricht University Medical Centre), Véronique Bataille(King's College London), Bohdan Lytvynenko(Shupyk National Healthcare University of Ukraine), Ricardo Vieira(Hospitais da Universidade de Coimbra), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Petr Arenberger(Charles University), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Jet Company (Czechia)), Axel Hauschild(Kiel University), Josep Malvehy(Instituto de Salud Carlos III), Maria Concetta Fargnoli(University of L'Aquila), Teresa Amaral(University of Tübingen), Aimilios Lallas(Aristotle University of Thessaloniki), Lars Bastholt(Odense University Hospital), Nicole Basset‐Séguin(Inserm), V. del Mármol(Université Libre de Bruxelles), Alexander C. J. van Akkooi(The University of Sydney), Paul Nathan(Mount Vernon Cancer Centre), Iris Zalaudek(University of Trieste), Ana‐Maria Forsea(Carol Davila University of Medicine and Pharmacy), Alexander J. Stratigos(National and Kapodistrian University of Athens), Ketty Peris(Università Cattolica del Sacro Cuore), Christoph Höller(Medical University of Vienna), Giovanni Pellacani(Sapienza University of Rome), Jean-Jacques Grob(Aix-Marseille Université), Brigitte Dréno(Inserm)
Cited by 320
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k